[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pik3ca-gene-mutation\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pik3ca-gene-mutation":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":4},"100659070","phase-1-a-phase-12a-study-of-k-1728-in-advanced-solid-tumors-100659070",false,"NCT07861932","A Phase 1\u002F2a Study of K-1728 in Advanced Solid Tumors","A First-in-Human Study of K-1728 Administered Alone and in Combination in Participants With Advanced or Metastatic Solid Tumors","PIKYMA-01","Key Inclusion Criteria:\n\n* Adults with advanced or metastatic solid tumors who are able to provide consent\n* Documented activating PIK3CA mutation\n* ECOG performance status 0 or 1\n* Adequate organ function\n\nKey Exclusion Criteria:\n\n* Active or untreated central nervous system disease\n* Clinical significant or uncontrolled cardiovascular disease\n* Significant or uncontrolled intercurrent illness\n* Pregnant or breastfeeding\n* Other protocol-defined exclusion criteria","ALL","18 Years",{"count":20,"type":21},110,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This first-in-human, open-label, multicenter study evaluates K-1728 administered as monotherapy and in combination in participants with advanced or metastatic solid tumors. The study assesses the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of K-1728.",[28,29,30],"Breast Neoplasms","Solid Tumors","PIK3CA Gene Mutation","NOT_YET_RECRUITING","2026-10-01",{"date":34,"type":35},"2026-10-06","ACTUAL",{"date":37,"type":21},"2026-10",{"date":39,"type":21},"2029-03",{"name":41,"class":42},"KymaThera, Inc.","INDUSTRY"]